The effect of survivin gene promoter polymorphism on breast cancer

Conclusion & Impact:In conclusion, the use of survivin gene polymorphism as a risk factor in breast cancer is recommended based on the results of this study.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Breast cancer · apoptosis inhibitor protein · survivin

Abstract

Breast cancer is the most common malignant tumor in women and accounts for about 25% of all cancer diagnoses. Survivin is a member of the apoptosis inhibitor protein family of antiapoptotic proteins. In our study, we investigated one of those, the survivin gene promoter 31G/C polymorphism. Included in this study were 111 breast cancer patients who were operated on in our hospital and 101 healthy female subjects. Blood samples from the healthy subjects and paraffin-embedded tissue samples from the patients were used for DNA extraction and subsequent genetic analysis. PCR-RFLP was used for genotype analysis. We established the clinicopathologic characteristics of patients. No significant difference was found between survivin 31G/C promoter polymorphism of tumor characteristics and breast cancer. Between the control and breast cancer groups, survivin promoter polymorphism 31G/C differences were not significantly different (P = 0.058). The risk of developing cancer, having the relevant GC or CC genotype, is 1.413 times higher than those having genotype GG (95% confidence interval: 1.040 to 1.918). Carrying the C allele was statistically significant in terms of susceptibility to breast cancer. In conclusion, the use of survivin gene polymorphism as a risk factor in breast cancer is recommended based on the results of this study.

Özet

Breast cancer is the most common malignant tumor in women and accounts for about 25% of all cancer diagnoses. Survivin is a member of the apoptosis inhibitor protein family of antiapoptotic proteins. In our study, we investigated one of those, the survivin gene promoter 31G/C polymorphism. Included in this study were 111 breast cancer patients who were operated on in our hospital and 101 healthy female subjects. Blood samples from the healthy subjects and paraffin-embedded tissue samples from the patients were used for DNA extraction and subsequent genetic analysis. PCR-RFLP was used for genotype analysis. We established the clinicopathologic characteristics of patients. No significant difference was found between survivin 31G/C promoter polymorphism of tumor characteristics and breast cancer. Between the control and breast cancer groups, survivin promoter polymorphism 31G/C differences were not significantly different (P = 0.058). The risk of developing cancer, having the relevant GC or CC genotype, is 1.413 times higher than those having genotype GG (95% confidence interval: 1.040 to 1.918). Carrying the C allele was statistically significant in terms of susceptibility to breast cancer. In conclusion, the use of survivin gene polymorphism as a risk factor in breast cancer is recommended based on the results of this study.

Keywords

Breast cancer apoptosis inhibitor protein survivin survivin gene promoter polymorphism SNP

🔖

Cite This Article

ALTIPARMAK, M. D., BİLGİÇ, C. İ., DENER, N. C., GÜNDÜZ, E., YENİDÜNYA, S., ACAR, M., ŞEN, M., GÜNDÜZ, M. (2014). The effect of survivin gene promoter polymorphism on breast cancer. Turkish Journal of Biology, Cilt: 38 - Sayı: 6, 858–866. https://ajindex.com/articles/181598

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Altieri DC (2001). The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7: 542–547.
Altieri DC (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46–54.
Ambrosini G, Adida C, Altieri DC (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917–921.
Ambrosini G, Adida C, Sirugo G, Altieri DC (1998). Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273: 11177–11182.
Bayram S, Akkız H, Bekar A, Akgöllü E (2011). The association between the survivin –31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol 35: 555–559. Borbély AA, Murvai M, Szarka K, Kónya J, Gergely L, Hernádi Z, Veress G (2007). Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 60: 303–306.
Borges Bdo N, Burbano RR, Harada ML (2011). Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med 11: 189–193.
Christensen LA, Finch RA, Booker AJ, Vasquez KM (2006). Targeting oncogenes to improve breast cancer chemotherapy. Cancer Rese 66: 4089–4094.
Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, Anagnou NP, Nikiteas N (2009). Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 24: 145–150.
Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE et al. (2008). Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60: 31–39.
Liu Y, Du F, Chen W, Yao M, Lv K, Fu P (2014). EIF5A2 is a novel chemoresistance gene in breast cancer. Breast Cancer. Mar 18. Qin C, Cao Q, Li P, Ju X, Wang M, Chen J, Wu Y, Meng X, Zhu J, Zhang Z et al. (2012). Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLoS One 7: e28829. Rödel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rödel F (2003). Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55: 1341–1347.
Srivastava K, Srivastava A, Mittal B (2012). Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep 39: 1509–1516.
Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S, Gazouli M (2010). Effects of caspase-9